Using the collaborative cross to elucidate genetic and immune factors mediating chikungunya virus neuropathogenesis - the alphavirus chikungunya virus (CHIKV) represents a RE-emerging public health…

Active Grant Awarded

Award ID
R01AI193490
Recipient
Awarding agency
Obligated
$962,661

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 5% complete
Place of performance
San Antonio, TX 78227, USA

Award details come from USAspending.gov.

About this award

The National Institute of Allergy and Infectious Diseases, within the National Institutes of Health and the Department of Health and Human Services, awarded Texas Biomedical Research Institute $962,661 on August 28, 2026, under Allergy and Infectious Diseases Research (CFDA 93.855) through Grant R01AI193490. The recipient, doing business as Southwest Foundation for Biomedical Research, will use the genetically diverse Collaborative Cross mouse population to develop immunocompetent, neurodevelopmentally appropriate mouse models of chikungunya virus (CHIKV)-induced neurological disease that recapitulate neuropathogenesis observed in humans. The work also aims to elucidate the role of the immune response in that disease, building on preliminary findings of differential mouse strain susceptibility to CHIKV neuroinvasion. Place of performance is San Antonio, Texas 78227, and the ultimate completion date is August 31, 2031.

Description

Using the collaborative cross to elucidate genetic and immune factors mediating chikungunya virus neuropathogenesis - the alphavirus chikungunya virus (CHIKV) represents a RE-emerging public health concern as mosquito vectors spread to new territories. Over 3.7 million cases of CHIKV infection have been reported in the americas over the last decade, including local transmission cases in the united states. While CHIKV typically induces arthritogenic disease, up to 25% of cases result in neurological disease, such as encephalitis and meningitis. Studies of human clinical cases and mouse models of infection with CHIKV and other alphaviruses suggest that host factors play a role in disease susceptibility, and the immune response, particularly T cells, primarily drives clinical disease and pathology. The limited accessibility and minimally regenerative nature of the central nervous system (CNS) prevent CHIKV neuropathogenesis studies from being performed in humans. This impediment supports the use of animal models, especially when evaluating the immune response to infection. However, most previous CHIKV neuropathogenesis studies have used pre-weanling or immunocompromised mice, as adult C57BL/6J mice are not susceptible to CHIKV neuroinvasion following subcutaneous inoculation, a more natural route of CHIKV infection. The objective of this proposal is to harness the power of the genetically diverse collaborative cross (CC) mouse population to develop urgently needed immunocompetent, neurodevelopmentally appropriate mouse models of CHIKV-induced neurological disease that accurately recapitulate CHIKV neuropathogenesis observed in humans and can be used to elucidate the role of the immune response in disease. The scientific premise of our proposal is based on robust preliminary findings, including differential susceptibility of mouse strains to CHIKV neuroinvasion, mouse and CHIKV-strain-dependent neurovirulence, and neurological disease correlating with infiltration of immune cells into the CNS. Based on our preliminary findings, our central hypothesis is that host genetic factors mediate CHIKV neuroinvasion and neuropathogenesis by altering the host immune response. We will test this hypothesis through two aims: 1) determine the role host genetic variation plays in neurological CHIKV infection and disease by characterizing CC mice that develop CHIKV-induced neurological disease similar to humans and identifying genomic regions driving susceptibility to CHIKV neuroinvasion, and 2) determine the role the immune response plays in CHIKV neuropathogenesis in mouse models and human neurological CHIKV samples using a combination of RNA sequencing, spatial transcriptomics, and digital histopathological analysis. Developing rigorous, translational mouse models that replicate the clinical and pathological features of CHIKV-induced disease in humans will enable our team to study and understand how CHIKV induces neurological disease and neuropathology. These models will help US achieve our long-term goal of developing effective countermeasures against this important human pathogen with pandemic potential.

Quick answers

Who received award R01AI193490?

R01AI193490 was awarded to Texas Biomedical Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 28, 2026.

How much is award R01AI193490 worth?

$962,661 has been obligated on R01AI193490.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award